Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients

Schmitt, Nicole C.; Page, B.R.

doi:10.1080/14992027.2017.1353710

Cited by 29 publications

(28 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The wide range of SNHL incidence rates makes it impossible to draw any conclusions on the severity of RT and CRT induced ototoxicity [10]. Studies on the incidence and severity of hearing loss in head and neck cancer patients are limited, but those studies suggest that the risk of hearing loss is greater with higher-dose regimens of cisplatin [11]. The use of cetuximab as an alternative to high-dose cisplatin and has been increasingly used to treat patients who concern about the toxicity of platinum chemotherapy.…”

Section: Fig 1 Magnetic Resonance Imaging (A) and Pet-ct (B) A Primentioning

confidence: 99%

Oropharyngeal Squamous Cell Carcinoma Treated Concurrently With Cetuximab: A Case Report of Intolerance to Cisplatin in Young Age

Plieskienė¹,

Česas²

2021

Health Sciences

View full text Add to dashboard Cite

Squamous cell carcinoma of the oropharynx is a common case of head and neck cancer related to human papillomavirus. We present a case of moderately (G2) differentiated squamous cell carcinoma, which responded well to concurrent radiotherapy with cetuximab after intolerance of cisplatin. A 37-year-old woman referred to our hospital for a locally advanced cancer of the base of tongue. Physical examination revealed an ulcerative tumor with spread to the supraglottic structures, and swelling of the right side cervical lymph node at group IIA. The histological diagnosis from a biopsy specimen was moderately differentiated p16 positive squamous cell carcinoma. The patient underwent cisplatin-based concurrent chemoradiotherapy. Two – three weeks after receiving an intravenous cisplatin dose 100 mg/m 2 for the first day of chemorradiation, the patient presented with profound bilateral sensorineural hearing loss. The cisplatin-based chemotherapy had changed to alternative agent. The patient continuously underwent concurrently radiation with cetuximab without the break of radical radiotherapy course. The patient experienced partial recovery of hearing after radical treatment of cancer. Complete clinical and radiological response of oropharyngeal squamous carcinoma was achieved. Conclusions. Toxicity with only one standard dose of cisplatin can be profound also in young age. This risk should be addressed when counseling patient prior to initiation of treatment. In case of platinum ineligibility, replacing cisplatin with less toxic agent cetuximab may be taken into consideration for p16 positive carcinoma of the oropharynx.

show abstract

Section: Fig 1 Magnetic Resonance Imaging (A) and Pet-ct (B) A Primentioning

confidence: 99%

Oropharyngeal Squamous Cell Carcinoma Treated Concurrently With Cetuximab: A Case Report of Intolerance to Cisplatin in Young Age

Plieskienė¹,

Česas²

2021

Health Sciences

View full text Add to dashboard Cite

show abstract

“…Such a statement is probably not useful on its own. Consider, also, the variability in reported incidence of ototoxicity across studies (Schmitt and Page 2017; Konrad-Martin et al 2017). Some of this heterogeneity is attributed to variations in disease, dosing and treatment schemes, methods of administration, co-administration of concurrent ototoxic agents or agents that potentiate ototoxicity (e.g., radiation), patient age, and other patient-related variables.…”

Section: Defining Ototoxic Changementioning

confidence: 99%

“…Literature on many ototoxic agents reveals a wide-ranging incidence of associated otopathology. For example, the incidence of ototoxicity from cisplatin-based chemotherapies for head and neck cancers ranges from 17 to 88%, depending, in part, on how hearing loss is defined (Schmitt and Page 2017). This ambiguous rate of occurrence limits the ability to prognosticate risk for patients and a lack of clear and consistently-defined outcomes across cohorts hampers efforts to determine efficacy of potentially otoprotective interventions.…”

Section: Introductionmentioning

confidence: 99%

Clinical trials, ototoxicity grading scales and the audiologist’s role in therapeutic decision making

King

Brewer

2017

International Journal of Audiology

View full text Add to dashboard Cite

show abstract

“…Cisplatin is one of the chemotherapeutic drugs widely used in clinic. It has shown anticancer activity in a variety of tumors including cancers of the ovaries, lung, and solid tumors of the head and neck [ 8 – 10 ]. However, the sensitivity of tumor cells to cisplatin will be significantly reduced after long-term use, resulting in acquired drug resistance [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Cisplatin loaded multiwalled carbon nanotubes reverse drug resistance in NSCLC by inhibiting EMT

Yang

Liu

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

Background Lung cancer is one of the important health threats worldwide, of which 5-year survival rate is less than 15%. Non-small-cell lung cancer (NSCLC) accounts for about 80% of all lung cancer with high metastasis and mortality. Methods Cisplatin loaded multiwalled carbon nanotubes (Pt-MWNTS) were synthesized and used to evaluate the anticancer effect in our study. The NSCLC cell lines A549 (cisplatin sensitive) and A549/DDP (cisplatin resistant) were used in our in vitro assays. MTT was used to determine Cancer cells viability and invasion were measured by MTT assay and Transwell assay, respectively. Apoptosis and epithelial-mesenchymal transition related marker proteins were measured by western blot. The in vivo anti-cancer effect of Pt-MWNTs were performed in male BALB/c nude mice (4-week old). Results Pt-MWNTS were synthesized and characterized by X-ray diffraction, Raman, FT-IR spectroscopy and scan electron microscopy. No significant cytotoxicity of MWNTS was detected in both A549/DDP and A549 cell lines. However, Pt-MWNTS showed a stronger inhibition effect on cell growth than free cisplatin, especially on A549/DDP. We found Pt-MWNTS showed higher intracellular accumulation of cisplatin in A549/DDP cells than free cisplatin and resulted in enhanced the percent of apoptotic cells. Western blot showed that application of Pt-MWNTS can significantly upregulate the expression level of Bax, Bim, Bid, Caspase-3 and Caspase-9 while downregulate the expression level of Bcl-2, compared with free cisplatin. Moreover, the expression level of mesenchymal markers like Vimentin and N-cadherin was more efficiently reduced by Pt-MWNTS treatment in A549/DDP cells than free cisplatin. In vivo study in nude mice proved that Pt-MWNTS more effectively inhibited tumorigenesis compared with cisplatin, although both of them had no significant effect on body weight. Conclusion Pt-MWNT reverses the drug resistance in the A549/DDP cell line, underlying its possibility of treating NSCLC with cisplatin resistance.

show abstract

Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients

Abstract: Newer cisplatin chemotherapy regimens using lower, weekly doses may be associated with a lower incidence and severity of hearing loss; however, large prospective studies are needed. Such information will be paramount to effective pre-treatment counselling of head and neck cancer patients.

Cited by 29 publications

References 27 publications

Oropharyngeal Squamous Cell Carcinoma Treated Concurrently With Cetuximab: A Case Report of Intolerance to Cisplatin in Young Age

Oropharyngeal Squamous Cell Carcinoma Treated Concurrently With Cetuximab: A Case Report of Intolerance to Cisplatin in Young Age

Clinical trials, ototoxicity grading scales and the audiologist’s role in therapeutic decision making

Cisplatin loaded multiwalled carbon nanotubes reverse drug resistance in NSCLC by inhibiting EMT

Contact Info

Product

Resources

About